Joel Block to Immunoglobulin G
This is a "connection" page, showing publications Joel Block has written about Immunoglobulin G.
Connection Strength
1.393
-
Tuberculosis infections and tumor necrosis factor alpha antagonists. Am J Ther. 2013 Jan; 20(1):73-8.
Score: 0.412
-
Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections. J Rheumatol. 2009 May; 36(5):914-7.
Score: 0.318
-
Etanercept therapy in patients with a positive tuberculin skin test. Clin Exp Rheumatol. 2007 Sep-Oct; 25(5):743-5.
Score: 0.285
-
Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet. 2002 Feb 16; 359(9306):579-80.
Score: 0.194
-
New therapeutic approaches for spondyloarthritis. Curr Opin Rheumatol. 2007 May; 19(3):259-64.
Score: 0.070
-
Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis. 2004 Aug 01; 39(3):295-9.
Score: 0.057
-
Mycobacteria tuberculosis peritonitis associated with etanercept therapy. Clin Exp Rheumatol. 2003 Jul-Aug; 21(4):526.
Score: 0.053
-
Antinucleic acid autoantibody responses of normal human origin: antigen specificity and idiotypic characteristics compared to patients with systemic lupus erythematosus and patients with monoclonal IgM. J Rheumatol Suppl. 1987 Jun; 14 Suppl 13:127-31.
Score: 0.004